Top

Published in:

01-12-2011

Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals

Authors: Mev Dominguez Valentin, Felipe Carneiro da Silva, Erika Maria Monteiro dos Santos, Bianca Garcia Lisboa, Ligia Petrolini de Oliveira, Fabio de Oliveira Ferreira, Israel Gomy, Wilson Toshihiko Nakagawa, Samuel Aguiar Junior, Mariana Redal, Carlos Vaccaro, Adriana Della Valle, Carlos Sarroca, Dirce Maria Carraro, Benedito Mauro Rossi

Published in: Familial Cancer | Issue 4/2011

Abstract

Lynch syndrome (LS) is an autosomal dominant syndrome that predisposes individuals to development of cancers early in life. These cancers are mainly the following: colorectal, endometrial, ovarian, small intestine, stomach and urinary tract cancers. LS is caused by germline mutations in DNA mismatch repair genes (MMR), mostly MLH1 and MSH2, which are responsible for more than 85% of known germline mutations. To search for germline mutations in MLH1 and MSH2 genes in 123 unrelated South American suspected LS patients (Bethesda or Amsterdam Criteria) DNA was obtained from peripheral blood, and PCR was performed followed by direct sequencing in both directions of all exons and intron–exon junctions regions of the MLH1 and MSH2 genes. MLH1 or MSH2 pathogenic mutations were found in 28.45% (34/123) of the individuals, where 25/57 (43.85%) fulfilled Amsterdam I, II and 9/66 (13.63%) the Bethesda criteria. The mutations found in both genes were as follows: nonsense (35.3%), frameshift (26.47%), splicing (23.52%), and missense (9%). Thirteen alterations (35.14%) were described for the first time. The data reported in this study add new information about MLH1 and MSH2 gene mutations and contribute to better characterize LS in Brazil, Uruguay and Argentina. The high rate of novel mutations demonstrates the importance of defining MLH1 and MSH2 mutations in distinct LS populations.

Available only for authorised users

Talseth-Palmer BA, McPhillips M, Groombridge C, Spigelman A, Scott RJ (2010) MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer. Hered Cancer Clin Pract 8:5PubMedCrossRef

Lynch HT, Shaw T, Lynch J, Grady W (2005) Histórico do câncer colorretal hereditário sem polipose: Síndrome de Lynch. In: Rossi B, Nakagawa W, Ferreira F, Aguiar Junior S, Lopes A (eds) Câncer de cólon, reto e ânus. Lemar/Tecmedd, pp 575–593

Chialina SG, Fornes C, Landi C, de la Vega Elena CD, Nicolorich MV, Dourisboure RJ, Solano A, Solis EA (2006) Microsatellite instability analysis in hereditary non-polyposis colon cancer using the Bethesda consensus panel of microsatellite markers in the absence of proband normal tissue. BMC Med Genet 7:1–5CrossRef

Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425PubMedCrossRef

Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef

Rodriguez-Bigas MA, Boland CR, Hamilton SR et al (1997) A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762PubMedCrossRef

Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRef

Yap HL, Chieng WS, Lim JR et al (2009) Recurring MLH1 deleterious mutations in unrelated Chinese Lynch syndrome families in Singapore. Fam Cancer 8:85–94PubMedCrossRef

Da Silva FC, Dominguez MV, Ferreira FO et al (2009) Mismatch repair genes in Lynch syndrome: a review. São Paulo Med J 127:46–51PubMedCrossRef

10.

Ou J, Niessen RC, Lützen A et al (2007) Functional analysis helps to clarify the clinical importance of unclassified variants in DNA mismatch repair genes. Hum Mutat 28:1047–1054PubMedCrossRef

11.

Ou J, Niessen RC, Vonk J et al (2008) A database to support the interpretation of human mismatch repair gene variants. Hum Mutat 29:1337–1341PubMedCrossRef

12.

Couch FJ, Rasmussen LJ, Hofstra R et al (2008) Assessment of functional effects of unclassified genetic variants. Hum Mutat 29:1314–1326PubMedCrossRef

13.

Baudi F, Fersini G, Lavecchia A et al (2005) A novel missense germline mutation in exon 2 of the hMSH2 gene in a HNPCC family from Southern Italy. Cancer Lett 223:285–291PubMedCrossRef

14.

Dominguez MV, Bastos EP, Santos EM et al (2008) Two new MLH1 germline mutations in Brazilian Lynch syndrome families. Int J Colorectal Dis 23:1263–1264PubMedCrossRef

15.

Greenblatt MS, Brody LC, Foulkes WD et al (2008) Locus-specific database and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum Mutat 29:1273–1281PubMedCrossRef

16.

Tunca B, Pedroni M, Cecener G et al (2010) Analysis of mismatch repair gene mutations in Turkish HNPCC patients. Fam Cancer 9(3):365–376PubMedCrossRef

17.

Mangold E, Pagenstecher C, Friedl W et al (2005) Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol 207:385–395PubMedCrossRef

18.

Martínez-Bouzas C, Beristain E, Ojembarrena E et al (2009) A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque Country, describing four new germline mutations. Fam Cancer 8:533–539PubMedCrossRef

19.

Tang R, Hsiung C, Wang JY et al (2009) Germ line MLH1 and MSH2 mutations in Taiwanese Lynch syndrome families: characterization of a founder genomic mutation in the MLH1 gene. Clin Genet 75:334–345PubMedCrossRef

20.

Pineda M, González S, Lázaro C et al (2010) Detection of genetic alterations in hereditary colorectal cancer screening. Mutat Res 693(1–2):19–31PubMed

21.

Perera T, Wijesuriya RE, Suraweera PH et al (2008) Prevalence of colorectal cancer and survival in patients from the Gampaha District, North Colombo region. Ceylon Med J 53:17–21PubMedCrossRef

22.

Nyström-Lahti M, Wu Y, Moisio AL et al (1996) DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet 5:763–769PubMedCrossRef

23.

[MMR] Mismatch Repair Genes Variant Database (2009) Data base. Available from: URL:http://www.med.mun.ca/mmrvariants (12 Jul 2009)

24.

Rossi BM, Lopes A, Oliveira Ferreira F et al (2002) hMLH1 and hMSH2 gene mutation in Brazilian families with suspected hereditary nonpolyposis colorectal cancer. Ann Surg Oncol 9:555–561PubMed

25.

Sarroca C, Valle AD, Fresco R et al (2005) Frequency of hereditary non-polyposis colorectal cancer among Uruguayan patients with colorectal cancer. Clin Genet 68:80–87PubMedCrossRef

26.

Giraldo A, Gómez A, Salguero G et al (2005) MLH1 and MSH2 mutations in Colombian families with hereditary nonpolyposis colorectal cancer (Lynch syndrome)- description of four novel mutations. Fam Cancer 4:285–290PubMedCrossRef

27.

Olilla S, Bebek DD, Jiricny J et al (2008) Mechanisms of pathogenicity in Human MSH2 missense mutants. Hum Mutat 29:1355–1363CrossRef

28.

Lastella P, Surdo NC, Resta N et al (2006) In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. BMC Genomics 7:243PubMedCrossRef

29.

Peltomäki P, Vasen HFA (1997) The international collaborative group on hereditary nonpolyposis colorectal cancer. Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. Gastroenterology 113:1146–1158PubMedCrossRef

30.

Apessos A, Mihalatos M, Danielidis I et al (2005) hMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients. Br J Cancer 92:396–404PubMed

31.

Sjöblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274PubMedCrossRef

32.

[INSIGHT] International Society of Hereditary Gastrointestinal Cancer (2009) Data base. Available from: URL: http://www.insight-group.org/ (12 Jul 2009)

33.

Rouleau E, Lefol C, Bourdon V et al (2009) Quantitative PCR high-resolution melting (qPCR-HRM) curve analysis, a new approach to simultaneously screen point mutations and large rearrangements: application to MLH1 germline mutations in Lynch syndrome. Hum Mutat 30:867–875PubMedCrossRef

34.

Isidro G, Veiga I, Matos P et al (2000) Four novel MSH2/MLH1 gene mutations in Portuguese HNPCC families. Hum Mutat 15:116PubMedCrossRef

35.

Lage PA, Albuquerque C, Sousa RG et al (2004) Association of colonic and endometrial carcinomas in Portuguese families with hereditary nonpolyposis colorectal carcinoma significantly increases the probability of detecting a pathogenic mutation in mismatch repair genes, primarily the MSH2 gene. Cancer 101:172–177PubMedCrossRef

36.

Ewald J, Rodrigue CM, Mourra N et al (2007) Immunohistochemical staining for mismatch repair proteins, and its relevance in the diagnosis of hereditary non-polyposis colorectal cancer. British J surg 94:1020–1027CrossRef

37.

Terdiman JP, Levin TR, Allen BA et al (2002) Hereditary nonpolyposis colorectal cancer in young colorectal cancer patients: high-risk clinic versus population-based registry. Gastroenterology 122:940–947PubMedCrossRef

38.

Rodrigues FC, Kawasaki-Oyama RS, Fo JF et al (2003) Analysis of CDKN1A polymorphisms: markers of cancer susceptibility? Cancer Genet Cytogenet 142:92–98PubMedCrossRef

39.

Martinez SL, Kolodner RD (2010) Functional analysis of human mismatch repair gene mutations identifies weak alleles and polymorphisms capable of polygenic interactions. PNAS 107:5070–5075PubMedCrossRef

40.

Kámory E, Tanyi M, Kolacsek O et al (2006) Two germline alterations in mismatch repair genes found in a HNPCC patient with poor family history. Pathol Oncol Res 12:228–233PubMedCrossRef

41.

Wimmer K, Etzler J (2008) Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 124:105–122PubMedCrossRef

Title: Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals
Authors: Mev Dominguez Valentin
Felipe Carneiro da Silva
Erika Maria Monteiro dos Santos
Bianca Garcia Lisboa
Ligia Petrolini de Oliveira
Fabio de Oliveira Ferreira
Israel Gomy
Wilson Toshihiko Nakagawa
Samuel Aguiar Junior
Mariana Redal
Carlos Vaccaro
Adriana Della Valle
Carlos Sarroca
Dirce Maria Carraro
Benedito Mauro Rossi
Publication date: 01-12-2011
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-011-9461-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Acinic cell carcinoma of the retromolar trigone region: expanding the tumor phenotype in Cowden syndrome?

The identification and management of hereditary diffuse gastric cancer in a large Jordanian family

Long-term outcomes, branch-specific expressivity, and disease-related mortality in von Hippel-Lindau type 2A

Concerns about inherited risk of breast cancer prior to diagnosis in Japanese patients with breast complaints

Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan

A survey of APC mutations in Quebec

Keynote webinar | Spotlight on antibody–drug conjugates in cancer